Skip to main content

Home/ OARS funding Biomed/ Group items tagged biomedical

Rss Feed Group items tagged

MiamiOH OARS

RFA-CA-19-013: Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improv... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers.  The purpose of this FOA is to develop Immuno-engineering to Improve Immunotherapy (i3) Centers, as new components of the Immuno-Oncology Translation Network (IOTN). The i3 Centers will be comprised of multi-disciplinary teams focused on developing and employing engineered immunotherapy approaches to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies. The overarching goals of the IOTN are to accelerate translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluate new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints. 
MiamiOH OARS

Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate Research E... - 0 views

  •  
    The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and clinical research workforce, to pursue further studies or careers in research.
MiamiOH OARS

NIH Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate Resear... - 0 views

  •  
    The over-arching goal of this NIH Blueprint R25 program is to support educational activities thatenhance the diversity of the biomedical, behavioral and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities. The fully integrated educational activities should prepare undergraduate students from diverse backgrounds nationally underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that have substantial enrollment of diverse undergraduates from populations underrepresented in the biomedical and behavioral sciences, b) a research-intensive institution that has an established neuroscience or neuroscience-related program, c) integrated curriculum/academic enhancement and research training activities designed to increase participants' preparation to enter doctoral programs in the neurosciences, and d) well-described plans to provide early communication and interaction between participating students and graduate neuroscience programs across the country.
MiamiOH OARS

Limited Competition: RCMI Research Coordination Network (RRCN) (U54 Clinical Trial Not ... - 0 views

  •  
    The RCMI Research Coordination Network (RRCN), formerly known as the RCMI Translational Research Network (RTRN), was established in 2007 to enhance collaboration across RCMI institutions. The network is designed to engage all stakeholders in the RCMI institutions, increase the quality and efficiency of basic biomedical, behavioral, and clinical research, facilitate study participant recruitment and retention, and increase the efficiency of the implementation and dissemination of research advances to improved health outcomes among minority and health disparity populations. Maintaining the longstanding networking and collaboration with the RCMI grantee community is key to the continued success of this program. The purpose of this funding opportunity announcement (FOA) is to provide infrastructure and research funding to support overall network coordination and collaboration, and to expand the Research Coordinating Center (RCC) and Data Coordinating Center (DCC) functions of the RRCN.
MiamiOH OARS

Minority Health and Health Disparities Research Training (MHRT) Program (T37) - 0 views

  •  
    The National Institute on Minority Health and Health Disparities (NIMHD) invites applications for the Minority Health and Health Disparities Research Training (MHRT) awards. The Program supports research training activities in minority health and health disparities research for individuals from diverse backgrounds, including groups underrepresented in biomedical, behavioral, clinical and social sciences research, at domestic institutions and/or at specified foreign low and middle income (LMIC) locations. This program is intended to promote both domestic and international training opportunities in a diverse and inclusive environment for eligible undergraduate, post-baccalaureate and graduate students, as well as for eligible residents, fellows and postdoctoral students.
MiamiOH OARS

Limited Competition: AIDS and Cancer Specimen Resource (ACSR)(UM1 Clinical Trials Not A... - 0 views

  •  
    Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits a single application for the continuation of the AIDS and Cancer Specimen Resource (ACSR). The eligible applicant institutions (which are the two current NCI-supported ACSR lead institutions) are expected to maintain the cooperative group structure and the activities of the ACSR. The primary objective of the ACSR will be to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated demographic data from patients with human immunodeficiency virus (HIV)-associated malignancies. In addition to serving acquired immunodeficiency syndrome (AIDS) and cancer researchers at large, the ACSR will specifically provide biorepository functions for another NCI supported initiative, the AIDS Malignancy Consortium (AMC). The AMC performs clinical trials research in the treatment and prevention of HIV-associated malignancies in the United States and Sub-Saharan Africa. As the AMC is currently expanding its agenda to include Latin America, it is expected that the ACSR will collaborate with the AMC to develop regional biorepository support for AMC activities in Latin American countries. The continuing ACSR must have appropriate strategies and capabilities to address several high priority areas of specimen acquisition including specific types of cancer (AIDS-defining as well as non-AIDS defining), types of biospecimens and accompanying clinical data, and biospecimens from geographic areas of interest.
MiamiOH OARS

Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Proje... - 0 views

  •  
    The National Institute on Aging invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.
MiamiOH OARS

Enhance Population Access to Comprehensive HIV/AIDS Services in Order to Achieve HIV/AI... - 0 views

  •  
    This notice of funding opportunity (NOFO) supports the acceleration of a comprehensive HIV prevention, care, and treatment program to achieve HIV epidemic control in selected Health Zones (HZs) in Kinshasa province. This aims to provide evidence-based interventions, including targeted HIV testing, to find more people living with HIV (PLHIV), especially among eligible contacts of HIV positive index cases, as well as community outreach through Orphan and Vulnerable Children (OVC) services; HIV prevention services; TB/HIV prevention, diagnosis, and treatment services; Prevention of Mother-to-Child Transmission (PMTCT) for general population and key population (KP); and associated laboratory and strategic information (SI) services. Through a stigma-free approach, the recipient will provide direct support and technical assistance to accelerate the HIV service delivery cascade and improve data quality and utilization for decision-making. The recipient will also work closely with the Ministry of Health (MOH) to strengthen the technical capacity of provincial and HZ Teams. Capable community organizations are expected to contribute by improving uptake of HIV services, linkage, and retention. The ultimate goal is the elimination of HIV by 2030.
MiamiOH OARS

RFA-AR-19-012: Research Innovations for Scientific Knowledge (RISK) for Skin and Rheuma... - 0 views

  •  
    The NIAMS Research Innovation for Scientific Knowledge (RISK) for  Skin and Rheumatic Diseases (R61/R33) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice.  This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms.  This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.
MiamiOH OARS

Crohn's & Colitis Foundation Issues Request for Proposals for IBD Fibrosis Initiative |... - 0 views

  •  
    Half of all Crohn's disease patients will develop disease complications, one of which is development of fibrotic strictures (fibrostenosis) leading to GI tract obstruction and severe clinical consequences. Fibrostenosis is also a serious problem for ulcerative colitis, with approximately 8 percent incidence over a lifetime. Currently there is no clinical solution for preventing or treating fibrostenosis in patients with inflammatory bowel disease (IBD) except for surgical intervention. Therefore, there is a great unmet need to understand fibrotic complications in IBD and how to prevent and treat them.
MiamiOH OARS

Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed) - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to support short-term exploratory, developmental, and transdisciplinary research to understand the immunologic events that occur during blood feeding by hematophagous arthropods. The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod salivary components; and (3) to understand the immunological events in the hematophagous arthropods following a blood meal.
MiamiOH OARS

Administrative Supplements to Promote Collaborative Activities in Basic Cancer Research... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to incentivize collaborative, multidisciplinary research across a broad area of challenging topics in basic cancer biology. These supplement applications must propose a collaboration between at least two researchers, one being the PI of the parent NCI grant. Awarded supplements will leverage and extend currently funded cancer research in the parent grant.
MiamiOH OARS

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative ... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.
MiamiOH OARS

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Preventio... - 0 views

  •  
    The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.
MiamiOH OARS

Alzheimer's Drug Discovery Foundation Issues RFP for Biomarker Studies | RFPs | PND - 0 views

  •  
    Grants of up to $300,000 over two years will be awarded in support of projects focused on the development of biomarkers previously identified in samples from well-characterized human subjects. Validated methods should be used in quantifying and qualifying biomarkers, with less enthusiasm for the development of novel technologies. Priority biomarker areas include companion biomarkers, neuroimaging, CSF and blood-based biomarkers, and functional activity measures.
MiamiOH OARS

Oxalosis and Hyperoxaluria Foundation Accepting Applications for Research Projects | RF... - 0 views

  •  
    Grants of up to $200,000 over two years will be awarded to support research with the potential to lead to new diagnostics, treatments, and a cure for primary hyperoxaluria and related conditions.
MiamiOH OARS

Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Al... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact HIV infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure.
MiamiOH OARS

2018 Part the Cloud: Translational Research Funding for Alzheimer's Disease - 0 views

  •  
    Applications will be accepted from academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study in humans to begin proving the scientific concept in humans. This award will support Phase 1 studies or pilot small- scale Phase 2a studies for repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer's disease (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. In addition, proposals may be considered that are POC to validate biological marker(s) of disease progression in a clinical trial environment. Any proposal must have a clear focus on Alzheimer's disease and related disorder and be translational in nature. All proposals should clearly and explicitly outline the measure to be investigated, the methods for study, and outcomes. Researchers from underrepresented groups are encouraged to apply.
MiamiOH OARS

PA-18-757: Administrative Supplements to NIGMS Predoctoral Training Grants for the Deve... - 0 views

  •  
    The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of activities aimed at broadening the training experience to better prepare individuals for careers in the biomedical research workforce.
MiamiOH OARS

RFA-FD-18-020: Three-Dimensional Approach for Modeling Nasal Mucociliary Clearance via ... - 0 views

  •  
    FDA's CDER is seeking a computational modeling approach to study the effects of mucociliary clearance on localized drug absorption in the nasal cavity. The modeling approach would utilize computational fluid dynamics (CFD) simulations of inhalation and droplet/particle transport to provide regional nasal spray deposition data, while the three-dimensional mucociliary clearance model would demonstrate localized drug absorption and indicate the efficacy of drug products that target specific nasal regions. The model should be adaptable to cases of interindividual variability, which may include variations in mucociliary clearance rates, changes in nasal geometry, and the presence of relevant disease states (e.g., nasal inflammation, changes in mucus properties, etc.).
1 - 20 of 40 Next ›
Showing 20 items per page